197 related articles for article (PubMed ID: 20059446)
21. Oral cyclophosphamide improves pulmonary function in scleroderma patients with fibrosing alveolitis: experience in one centre.
Beretta L; Caronni M; Raimondi M; Ponti A; Viscuso T; Origgi L; Scorza R
Clin Rheumatol; 2007 Feb; 26(2):168-72. PubMed ID: 16614793
[TBL] [Abstract][Full Text] [Related]
22. Determinants of pulmonary function improvement in patients with scleroderma and interstitial lung disease.
Tzelepis GE; Plastiras SC; Karadimitrakis SP; Vlachoyiannopoulos PG
Clin Exp Rheumatol; 2007; 25(5):734-9. PubMed ID: 18078622
[TBL] [Abstract][Full Text] [Related]
23. Effect of Bosentan on systemic sclerosis-associated interstitial lung disease ineligible for cyclophosphamide therapy: a prospective open-label study.
Furuya Y; Kuwana M
J Rheumatol; 2011 Oct; 38(10):2186-92. PubMed ID: 21885489
[TBL] [Abstract][Full Text] [Related]
24. Assessments of pulmonary involvement in patients with systemic sclerosis.
Gohari Moghadam K; Gharibdoost F; Parastandechehr G; Salehian P
Arch Iran Med; 2011 Jan; 14(1):22-6. PubMed ID: 21194257
[TBL] [Abstract][Full Text] [Related]
25. [Efficacy of ab initio immunosuppressive therapy and steroid-sparing effect in interstitial lung disease associated with antisynthetase antibody syndrome].
Franzolini N; Quartuccio L; De Marchi G; De Vita S
Reumatismo; 2007; 59(3):202-8. PubMed ID: 17898879
[TBL] [Abstract][Full Text] [Related]
26. Low-dose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis (SSc-ILD): efficacy of maintenance immunosuppression in responders and non-responders.
Iudici M; Cuomo G; Vettori S; Bocchino M; Sanduzzi Zamparelli A; Cappabianca S; Valentini G
Semin Arthritis Rheum; 2015 Feb; 44(4):437-44. PubMed ID: 25282395
[TBL] [Abstract][Full Text] [Related]
27. Evaluation and management of scleroderma lung disease using bronchoalveolar lavage.
Silver RM; Miller KS; Kinsella MB; Smith EA; Schabel SI
Am J Med; 1990 May; 88(5):470-6. PubMed ID: 2337105
[TBL] [Abstract][Full Text] [Related]
28. Correlation of cough with disease activity and treatment with cyclophosphamide in scleroderma interstitial lung disease: findings from the Scleroderma Lung Study.
Theodore AC; Tseng CH; Li N; Elashoff RM; Tashkin DP
Chest; 2012 Sep; 142(3):614-621. PubMed ID: 22156609
[TBL] [Abstract][Full Text] [Related]
29. Intravenous cyclophosphamide for interstitial lung disease associated to systemic sclerosis: results with an 18-month long protocol including a maintenance phase.
Airò P; Danieli E; Rossi M; Frassi M; Cavazzana I; Scarsi M; Grottolo A; Franceschini F; Zambruni A
Clin Exp Rheumatol; 2007; 25(2):293-6. PubMed ID: 17543156
[TBL] [Abstract][Full Text] [Related]
30. CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis.
Prasse A; Pechkovsky DV; Toews GB; Schäfer M; Eggeling S; Ludwig C; Germann M; Kollert F; Zissel G; Müller-Quernheim J
Arthritis Rheum; 2007 May; 56(5):1685-93. PubMed ID: 17469163
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of cyclophospamide in the treatment of interstitial lung disease associated with systemic sclerosis.
Espinosa G; Simeón CP; Plasín MÁ; Xaubet A; Muñoz X; Fonollosa V; Cervera R; Vilardell M
Arch Bronconeumol; 2011 May; 47(5):239-45. PubMed ID: 21458128
[TBL] [Abstract][Full Text] [Related]
32. Bronchoalveolar lavage for evaluation and management of scleroderma disease of the lung.
Behr J; Vogelmeier C; Beinert T; Meurer M; Krombach F; König G; Fruhmann G
Am J Respir Crit Care Med; 1996 Aug; 154(2 Pt 1):400-6. PubMed ID: 8756813
[TBL] [Abstract][Full Text] [Related]
33. The efficacy of oral cyclophosphamide plus prednisolone in early diffuse systemic sclerosis.
Calguneri M; Apras S; Ozbalkan Z; Ertenli I; Kiraz S; Ozturk MA; Celik I
Clin Rheumatol; 2003 Oct; 22(4-5):289-94. PubMed ID: 14579158
[TBL] [Abstract][Full Text] [Related]
34. Relationship Between Abnormalities on High-Resolution Computerized Tomography, Pulmonary Function, and Bronchoalveolar Lavage in Progressive Systemic Sclerosis.
Cakmak G; Selcuk Can T; Gundogdu S; Akman C; Ikitimur H; Musellim B; Ongen G
Sarcoidosis Vasc Diffuse Lung Dis; 2016 Dec; 33(4):349-354. PubMed ID: 28079847
[TBL] [Abstract][Full Text] [Related]
35. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis.
White B; Moore WC; Wigley FM; Xiao HQ; Wise RA
Ann Intern Med; 2000 Jun; 132(12):947-54. PubMed ID: 10858177
[TBL] [Abstract][Full Text] [Related]
36. Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline.
Plastiras SC; Karadimitrakis SP; Ziakas PD; Vlachoyiannopoulos PG; Moutsopoulos HM; Tzelepis GE
Arthritis Rheum; 2006 Aug; 55(4):598-602. PubMed ID: 16874782
[TBL] [Abstract][Full Text] [Related]
37. [Pulmonary involvement in sclerodermia].
Paone G; Di Michele L; Mattia P; Tonnarini R; Lucifora V; Fiorucci F
Minerva Med; 1994 Jun; 85(6):293-300. PubMed ID: 8084431
[TBL] [Abstract][Full Text] [Related]
38. Regional differences in bronchoalveolar lavage and thoracic high-resolution computed tomography results in dyspneic patients with systemic sclerosis.
Clements PJ; Goldin JG; Kleerup EC; Furst DE; Elashoff RM; Tashkin DP; Roth MD
Arthritis Rheum; 2004 Jun; 50(6):1909-17. PubMed ID: 15188367
[TBL] [Abstract][Full Text] [Related]
39. [Correlation between bronchoalveolar lavage and lung function in patients with systemic sclerosis and rheumatoid arthritis].
Pejcić T; Stanković I; Rancić M; Djordjević I; Ristić L; Vojinović J
Srp Arh Celok Lek; 2005 Dec; 133 Suppl 2():129-33. PubMed ID: 16535997
[TBL] [Abstract][Full Text] [Related]
40. Effects of oral cyclophosphamide and prednisolone therapy on the endothelial functions and clinical findings in patients with early diffuse systemic sclerosis.
Apras S; Ertenli I; Ozbalkan Z; Kiraz S; Ozturk MA; Haznedaroglu IC; Cobankara V; Pay S; Calguneri M
Arthritis Rheum; 2003 Aug; 48(8):2256-61. PubMed ID: 12905480
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]